Compare MSGE & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSGE | HTFL |
|---|---|---|
| Founded | 2020 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | N/A | 2025 |
| Metric | MSGE | HTFL |
|---|---|---|
| Price | $59.27 | $37.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $52.40 | $39.50 |
| AVG Volume (30 Days) | 282.9K | ★ 968.0K |
| Earning Date | 02-05-2026 | 02-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $962,282,000.00 | $161,881,000.00 |
| Revenue This Year | $9.47 | $40.42 |
| Revenue Next Year | $5.52 | $22.27 |
| P/E Ratio | $82.63 | ★ N/A |
| Revenue Growth | 0.68 | ★ 85.70 |
| 52 Week Low | $28.29 | $25.38 |
| 52 Week High | $61.64 | $41.22 |
| Indicator | MSGE | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 72.58 | N/A |
| Support Level | $58.79 | N/A |
| Resistance Level | $61.64 | N/A |
| Average True Range (ATR) | 1.63 | 0.00 |
| MACD | 0.42 | 0.00 |
| Stochastic Oscillator | 73.93 | 0.00 |
Madison Square Garden Entertainment Corp provides live entertainment, delivering unforgettable experiences while forging deep connections with diverse and passionate audiences. The company's portfolio includes a collection of world-renowned venues - New York's Madison Square Garden, The Theater at Madison Square Garden, Radio City Music Hall, and Beacon Theatre; and The Chicago Theatre - that showcase a broad array of sporting events, concerts, family shows, and special events for millions of guests annually. In addition, the company features the original production, the Christmas Spectacular Starring the Radio City Rockettes, which has been a holiday tradition for 89 years.
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.